RLMD News and Press, Relmada Therapeutics Inc. From 08/10/21

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results PR Newswire NEW YORK , Aug. 10, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central ...

Relmada Therapeutics to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 10, 2021 PR Newswire NEW YORK , Aug. 5, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressi...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Relmada Therapeutics Stock Rises on Positive Drug Trial Results” Relmada Therapeutics (NASDAQ: RLMD) , Inc.climbed over 21% in premarket trading after the company ...

Shares of Relmada Therapeutics (NASDAQ: RLMD) , a clinical-stage biopharmaceutical company, popped in response to a positive clinical trial readout with the company's lead candidate. Investors excited about REL-1017's positive human abuse potential trial results pushed the stock 37%...

Relmada Therapeutics (RLMD) announces top-line results of the human abuse potential ((HAP)) study with REL-1017, the company's lead candidate in Phase 3 development for the treatment major depressive disorder ((MDD)).Top-line results showed that all three doses of REL-1017 (25 mg, 75 mg ...

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential - All tested doses of REL-1017, including the maximum tolerated dose, showed a highly statistically significant difference in abuse potential vs. oxycodone with p-values...

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC PR Newswire NEW YORK , July 20, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-sta...

The following slide deck was published by Relmada Therapeutics, Inc. in conjunction with this event. For further details see: Relmada Therapeutics (RLMD) Presents At 3rd Annual CNS Virtual Forum - Slideshow

Relmada Therapeutics, Inc.’s (RLMD) sole clinical asset, oral antidepressant therapy esmethadone, is undergoing two pivotal trials for the treatment of MDD. Phase 2 study data demonstrate a rapid onset of action that no other currently approved oral therapy can boast. Despi...

Relmada Therapeutics to Present Data at the College on Problems of Drug Dependence 83rd Annual Scientific Meeting PR Newswire NEW YORK , June 15, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressi...